Results 1 to 10 of about 10,191 (205)

The Effects of Cabergoline Compared to Dienogest in Women with Symptomatic Endometrioma

Fertility & Reproduction, 2021
Background: New vessel formation or neovascularization has been recognized as a feature of endometriosis. Treatment with cabergoline suppresses cell proliferation and vascular-endothelial-growth-factor-mediated angiogenesis, thereby promoting regression ...
Mehnaz Mustary Shume, Jesmine Banu, Shakeela Ishrat, Serajoom Munira, Muhammad Jasim Uddin, Sabiha Sultana   +5 more
doaj   +1 more source

Electrocatalytic determination of levodopa in presence of cabergoline using carbon paste electrode modified with graphene quantum dots/2-chlorobenzoyl ferrocene/ionic liquid

Journal of Electrochemical Science and Engineering, 2021
The electrochemical sensor was fabricated for the simultaneous determination of levodopa and cabergoline using carbon paste electrode (CPE) modified with graphene quantum dots (GQD), 2-chlorobenzoyl ferrocene (2CBF) and ionic liquid (IL).
Peyman Mohammadzadeh Jahani
doaj   +1 more source

Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. [PDF]

PLoS ONE, 2014
Several lines of evidence demonstrate that oxidative stress is involved in the pathogenesis of neurodegenerative diseases, including Parkinson's disease. Potent antioxidants may therefore be effective in the treatment of such diseases.
Haruki Odaka, Tadahiro Numakawa, Naoki Adachi, Yoshiko Ooshima, Shingo Nakajima, Yusuke Katanuma, Takafumi Inoue, Hiroshi Kunugi   +7 more
doaj   +1 more source

Cabergoline

Reactions Weekly, 2006
europepmc   +3 more sources

Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study

BMC Endocrine Disorders, 2020
Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr, Thida C. Tan, Joan C. Lo, Jonathan G. Zaroff, Grace H. Tabada, Jingrong Yang, Alan S. Go   +6 more
doaj   +1 more source

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells

Frontiers in Endocrinology, 2022
The mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to display antiproliferative effects on a wide spectrum of tumors. In vitro studies demonstrated that everolimus inhibited pituitary neuroendocrine tumor (PitNET) cell growth in
Federica Mangili, Emanuela Esposito, Donatella Treppiedi, Rosa Catalano, Giusy Marra, Genesio Di Muro, Anna Maria Barbieri, Marco Locatelli, Marco Locatelli, Andrea G. Lania, Andrea G. Lania, Alessandra Mangone, Alessandra Mangone, Anna Spada, Maura Arosio, Maura Arosio, Erika Peverelli, Giovanna Mantovani, Giovanna Mantovani   +18 more
doaj   +1 more source

A Combination of Exercise and Therapy with Cabergoline Attenuate Disturbances of Pituitary-Gonadal Hormones in Hyperprolactinemic Male Patients [PDF]

Montenegrin Journal of Sports Science and Medicine, 2020
This study aimed to investigate whether cabergoline therapy alone for six months or in combination with a light exercise programme for an additional three months can attenuate hyperprolactinemia in 13 male patients (range: 22 to 45 yrs.) through ...
Mohammad Fayiz AbuMoh'd, Samir Qasim, Nesreen Bataineh, Loay Salman   +3 more
doaj   +1 more source

Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas [PDF]

Endocrinology and Metabolism, 2014
BackgroundCabergoline is typically effective for treating prolactinomas; however, some patients display cabergoline resistance, and the early characteristics of these patients remain unclear.
Youngki Lee, Cheol Ryong Ku, Eui-Hyun Kim, Jae Won Hong, Eun Jig Lee, Sun Ho Kim   +5 more
doaj   +1 more source

Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease

Journal of Pharmacological Sciences, 2006
.: Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice.
Akiko Nakatsuka, Masahiro Nagai, Hayato Yabe, Noriko Nishikawa, Takuo Nomura, Hiroyoko Moritoyo, Takashi Moritoyo, Masahiro Nomoto   +7 more
doaj   +1 more source

Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

BMC Pharmacology and Toxicology, 2021
Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby, Hekma A. Abd El Latif, Mohamed El Yamani, May Ahmed Galal, Sherifa Kamal, Ikhlas Sindi, Raneem Masaood   +6 more
doaj   +1 more source